Adenovirus Vector Manufacturing Platform Using CIMmultus® QA Column To Produce Safer Vaccines Cheaper

Source: Sartorius

By K. Vrabec, H. Jug, A. Mavri, I. Petrovic Koshmak, V. Fujs, M. Leskovec, and A. Štrancar

Covid vaccine-GettyImages-1336518535

After two decades, adenovirus has garnered renewed attention and is now employed as a delivery vehicle for COVID-19 vaccines. To reduce vaccine side effects, ensuring the purity of the virus is of utmost importance. Consequently, there is a continuous need for refining vaccine purity and enhancing impurity detection methods. In this study, we present a second-generation purification procedure for adenoviral vectors based on monolith chromatography, utilizing CIMmultus® QA and the accompanying analytical tools. This novel industrial process secures safer products and enhances purity at higher yields. Large-scale vaccine manufacturing during the pandemic represents significant challenges, primarily in terms of production time and costs. The high capacity of the CIMmultus® QA columns utilized in this process effectively overcomes the raw material supply bottlenecks.

access the Poster!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader